Dr. Sandra D'Angelo, MD
Claim this profileMemorial Sloan Kettering Cancer Center
Studies Soft Tissue Sarcoma
Studies Liposarcoma
10 reported clinical trials
18 drugs studied
Area of expertise
1Soft Tissue Sarcoma
Stage IV
Stage III
metastatic
2Liposarcoma
Stage IV
metastatic
locally advanced
Affiliated Hospitals
Clinical Trials Sandra D'Angelo, MD is currently running
Retifanlimab + Chemotherapy
for Soft Tissue Sarcoma
This study is being done to find out whether the study drug Retifanlimab, a monoclonal antibody against the PD-1 protein, combined with gemcitabine and docetaxel, is a safe and effective treatment for your disease. Gemcitabine and docetaxel are chemotherapy drugs that are commonly used to treat soft tissue sarcoma. Retifanlimab is an experimental drug that boosts the immune system's ability to fight cancer cells. The study researchers think that Retifanlimab may help gemcitabine and docetaxel work better against soft tissue sarcoma that is either locally advanced or has spread beyond its original location (metastasized), and it cannot be removed with surgery (unresectable).
Recruiting1 award Phase 1 & 213 criteria
Etrumadenant + Zimberelimab
for Sarcoma
This trial is testing a combination of two drugs, etrumadenant and zimberelimab, to treat patients with advanced dedifferentiated liposarcoma (DDLS). These patients have cancer that has come back, spread, or cannot be removed by surgery. Etrumadenant stops cancer cells from growing, while zimberelimab helps the immune system fight the cancer.
Recruiting1 award Phase 2
More about Sandra D'Angelo, MD
Clinical Trial Related5 years of experience running clinical trials · Led 10 trials as a Principal Investigator · 3 Active Clinical TrialsTreatments Sandra D'Angelo, MD has experience with
- Nivolumab
- NKTR-214
- Docetaxel
- Gemcitabine
- Retifanlimab
- Avelumab
Breakdown of trials Sandra D'Angelo, MD has run
Soft Tissue Sarcoma
Liposarcoma
Cancer
Sarcoma
Uterine Leiomyosarcoma
Other Doctors you might be interested in
Frequently asked questions
Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the ‘trial drug’ — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
What does Sandra D'Angelo, MD specialize in?
Sandra D'Angelo, MD focuses on Soft Tissue Sarcoma and Liposarcoma. In particular, much of their work with Soft Tissue Sarcoma has involved Stage IV patients, or patients who are Stage III.
Is Sandra D'Angelo, MD currently recruiting for clinical trials?
Yes, Sandra D'Angelo, MD is currently recruiting for 3 clinical trials in New York New York. If you're interested in participating, you should apply.
Are there any treatments that Sandra D'Angelo, MD has studied deeply?
Yes, Sandra D'Angelo, MD has studied treatments such as Nivolumab, NKTR-214, Docetaxel.
What is the best way to schedule an appointment with Sandra D'Angelo, MD?
Apply for one of the trials that Sandra D'Angelo, MD is conducting.
What is the office address of Sandra D'Angelo, MD?
The office of Sandra D'Angelo, MD is located at: Memorial Sloan Kettering Cancer Center, New York, New York 10065 United States. This is the address for their practice at the Memorial Sloan Kettering Cancer Center.
Is there any support for travel costs?
The coverage of travel expenses can vary greatly between different clinical trials. Please see more financial detail in the trials you’re interested to apply.